Skip to main content

Part of the book series: Developments in Oncology ((DION,volume 23))

  • 16 Accesses

Abstract

Presently, attempts to pharmacologically antagonize estrogen action are impeded by the weak estrogenic activity of the currently available estrogen antagonists. Most antiestrogens, rather than being pure antagonists, possess varying degrees of estrogen agonist activity. Thus, the action of estrogens can be antagonized only to the point where the agonist activity of the antiestrogen begins to be expressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen with a new benzothiophene antiestrogen. Life Sci (32): 1031–1036, 1983.

    Article  PubMed  CAS  Google Scholar 

  2. Black LJ, Jones CD, Goode RL: Differential interaction of antiestrogens with cytosol estrogen receptors. Mol Cell Endocrinol (22): 95–103, 1981.

    Article  PubMed  CAS  Google Scholar 

  3. Gale K: Treatment of advanced breast cancer with aminoglutethimide. Cancer Res suppl (42): 3389–3396, 1982.

    Google Scholar 

  4. Heuson JC, Coume A, Stagnet M: Clinical trial of 2-Br-alpha-ergocryptine (CB154) in advanced breast cancer. Europ J Cancer (8): 155–159, 1972.

    Article  Google Scholar 

  5. Clemens JA, Shaar CJ: Inhibition by ergocornine of initiation and growth of 7,12-dimethylbenzanthracene induced mammary tumors in rats: effect of tumor size. Proc Soc Exp Biol Med (139): 659–662, 1972.

    PubMed  CAS  Google Scholar 

  6. Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci (32): 2869–2875, 1983.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

K. R. Harrap W. Davis A. H. Calvert

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Clemens, J.A., Black, L.J., Zerbe, R.L. (1984). The Pharmacology of a New Antiestrogen. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_69

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3837-6_69

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3839-0

  • Online ISBN: 978-1-4613-3837-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics